APP Pharmaceuticals (APPX) Receives Final Approval for Generic Kytril
More News related to APPX
- APP Pharmaceuticals (APPX) Reports Slightly Higher Q2 Earnings; Issues Soft FY08 Guidance
- Unusual 11 Mid-Day Movers 7/7: RDN, APPX, IGLD, MPG Higher; VRTU, ININ, FBN, OFIX Lower
- Pre-Open Movers 7/7: APP Pharmaceuticals (APPX) Up on Buyout; Marshall & Ilsley (MI) Lower After Predicting Large Q2 Loss
- Fresenius Acquires APP Pharmaceuticals (APPX) For $23/Share, Plus An Extra $6 If Results are Meet
- APP Pharmaceuticals (APPX) Receives Final Approval for Generic Kytril
APP Pharmaceuticals, Inc. (Nasdaq: APPX) received final approvals from the FDA of its Abbreviated New Drug Applications (ANDAs) for Granisetron Hydrochloride Injection, 1 mg/mL, 1 mL single dose, and 1mg/mL, 4mL multiple dose vials, the generic equivalent of Hoffmann-LaRoche's Kytril Injection.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
